A randomized controlled trial in coronary artery disease (CAD) patients demonstrated that 8 weeks of crocin supplementation (30 mg/day) significantly reduced serum ox-LDL and MCP-1 while upregulating SIRT1 and AMPK gene expression and downregulating LOX1 and NF-κB in peripheral blood mononuclear cells (60). This evidence concerns the gene CCL2 and coronary artery disorder.